

## Supplementary Online Content

Guihard B, Chollet-Xémard C, Lakhnati P. Effect of rocuronium vs succinylcholine on endotracheal intubation success rate among patients undergoing out-of-hospital rapid sequence intubation: a randomized clinical trial. *JAMA*. doi:10.1001/jama.2019.18254

Statistical analysis plan

This supplementary material has been provided by the authors to give readers additional information about their work.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

# Statistical Analysis Plan

## Comparison of Succinylcholine and Rocuronium for Prehospital Emergency Intubation

### (The CURASMUR study)

### A no inferiority Randomized Clinical Trial

VERSION	DATE	REASON FOR UPDATE
1.0	31/10/2017	

Senior Statistician : C.Ferdynus \_\_\_\_\_ Signature (Date) \_\_\_\_\_

Methodologist : C.Marimoutou \_\_\_\_\_ Signature (Date) \_\_\_\_\_

Principal Investigator : X.Combes \_\_\_\_\_ Signature (Date) \_\_\_\_\_

22	TABLE DES MATIERES	
23		
24	DESIGN	2
25	OBJECTIVES	3
26	Main Objective	<b>Error! Bookmark not defined.</b>
27	Secondary Objectivess	<b>Error! Bookmark not defined.</b>
28	OUTCOMES	ERROR! BOOKMARK NOT DEFINED.
29	Primary Outcome	<b>Error! Bookmark not defined.</b>
30	Secondary Outcomes	<b>Error! Bookmark not defined.</b>
31	ELIGIBILITY CRITERIA	ERROR! BOOKMARK NOT DEFINED.
32	Inclusion criteria	<b>Error! Bookmark not defined.</b>
33	Non-inclusion criteria	<b>Error! Bookmark not defined.</b>
34	SAMPLE SIZE	ERROR! BOOKMARK NOT DEFINED.
35	DESCRIPTIVE ANALYSES	ERROR! BOOKMARK NOT DEFINED.
36	MANAGEMENT OF MISSING DATA	ERROR! BOOKMARK NOT DEFINED.
37	STATISTICAL ANALYSES	ERROR! BOOKMARK NOT DEFINED.
38	Analysis of primary outcome	
39	Analysis of secondary outcomes	5
40	ADVERSE EVENTS	6
41	CONCOMITANTS TREATMENTS	ERROR! BOOKMARK NOT DEFINED.
42	SUBGROUP ANALYSES	
43	SENSITIVITY ANALYSIS	ERROR! BOOKMARK NOT DEFINED.
44	TABLES TEMPLATE	ERROR! BOOKMARK NOT DEFINED.
45		
46		
47		

## 48 Study design

49 This is a randomized non-inferiority trial comparing two muscle relaxants (Rocuronium versus  
50 Succinylcholine) used for intubation in pre-hospital setting . The study is a single blind study (patient  
51 blinded) (patient).

52 Randomization was defined by block and stratified by center. Numbered, opaque and sealed  
53 envelopes were used in each ambulance for the assignment of the type of curares.

## 54 Objectives

### 55 Main objective

56 The main objective of the study is to demonstrate that emergency intubation conditions are non-  
57 inferior when Rocuronium is used in comparison with Succinylcholine in fast sequence induction  
58 sedation.

### 59 Secondary objectives

60 Secondary objectives assessing effectiveness of Rocuronium are:

- 61 - Assessment of the quality of direct laryngoscopy, using the classification of Cormack and  
62 Lehane
- 63 - Measure of the overall difficulty of the intubation process evaluated by the difficult  
64 intubation score (IDS)
- 65 - Assessment of intubation conditions using the Copenhagen score
- 66 - Assessment of the need for use of difficult intubation devices (Stylet, Gum Elastic bougie,  
67 Intubating laryngeal mask airway, Cricothyrotomy)
- 68 - Assessment of the tolerance of the 2 treatments, comparing the rate of complications  
69 observed with the use of Rocuronium or Succinylcholine

## 70 Outcomes

### 71 Primary outcome

72 The primary outcome is the proportion of successful intubation at first laryngoscopy in the two  
73 groups.

### 74 Secondary outcomes

- 75 - Distribution of grades of Cormack and Lehane classification in 2 treatment arms
- 76 - The difficult intubation score (IDS) in the 2 treatment groups
- 77 - Copenhagen score in the 2 treatment groups
- 78 - Proportion of use of difficult intubation devices (Stylet, Gum Elastic bougie, Intubating  
79 laryngeal mask airway, Cricothyrotomy) in the 2 treatment groups
- 80 - Proportion of immediate complications (in the first 15 minutes) following intubation  
81 according to the type of paralytic agent used: hypotension, cardiac arrhythmias, cardiac  
82 arrest, pulmonary inhalation, occurrence of episodes of arterial hypoxemia, allergic reaction

83 **Eligibility criteria**

84 **Inclusion criteria**

85 All adult patients with spontaneous cardiac activity requiring endotracheal intubation in the pre  
86 hospital setting were included in the study.

87 **Non-inclusion criteria**

- 88 - Minor patients- Pregnant women
- 89 - Presence of a contraindication to succinylcholine:
  - 90 ○ Personal or family history of recognized malignant hyperthermia
  - 91 ○ Allergy recognized with succinylcholine
  - 92 ○ Congenital muscle damage
  - 93 ○ Myasthenia
  - 94 ○ Certain hyperkalemia
  - 95 ○ Open-eye ophthalmic surgery
  - 96 ○ Congenital deficiency in known plasma pseudocholinesterases
- 97 - Presence of a contraindication to Rocuronium: recognized allergy to Rocuronium
- 98 - Presence of a contraindication to Sugammadex: allergy recognized to Sugammadex
- 99 - Patient not affiliated to a social insurance (beneficiary or beneficiary)

100 **Sample size**

101 The assessment of the number of patients required was made assuming a proportion of intubation  
102 successful at the first laryngoscopy of 75% and a margin of non-inferiority of 7%.

103 Under these assumptions, the number of subjects to be included was 602 patients per group (1204  
104 patients in total) to demonstrate that the intubation rate at the first trial is not inferior in the  
105 Rocuronium group compared with the Succinylcholine group at unilateral alpha risk of 2.5% and a  
106 beta risk of 20%.

107 An additional inclusion safety margin related to the risk of protocol deviations related to "field"  
108 inclusion and emergency randomization increased the number of subjects to be included to 650 per  
109 group (1300 to total).

110

## 111 Descriptive analyses

112 Characteristics of patients in each group will be summarized in a descriptive table. Descriptive  
113 statistical analysis will include for each quantitative variable: the mean, the standard deviation, the  
114 minimums and maximums, as well as the median and the quartiles. The qualitative variables will be  
115 expressed as frequencies and proportions. The standardized difference between the two groups will  
116 also be calculated for each variable and presented in this same table.

117 A descriptive analysis by center will be carried out. Patient characteristics included by center will be  
118 presented in a descriptive table.

## 119 Management of missing data

120 Prior to the analyses, a completion of the missing data will be carried out, if necessary, using a  
121 multiple imputation method. The hypothesis adopted regarding the mechanism of occurrence of the  
122 missing data will be a so-called Missing At Random (MAR) hypothesis. The Missing Not At Random  
123 hypothesis (MNAR) will also be tested. Imputations will be made for the primary outcome, the  
124 secondary outcomes, and the covariates.

## 125 Statistical analyses

126 Analyses of the primary outcome and the secondary outcomes will be presented in a summary table.  
127 Qualitative variables will be presented as frequencies and proportions. Quantitative variables will be  
128 presented as mean and standard deviation. The ordinal variables will be presented as median and  
129 quartiles.

130 All statistical analyses will be performed using SAS 9.4 software (SAS Institute Cary Inc).

## 131 Analysis of primary outcome

132 The non-inferiority between the proportions of successful intubation in the two treatment arms will  
133 be tested using the Dunnett and Gent method. The equivalence test will be a one-sided test based  
134 on the assumption of a non-inferiority margin  $\delta$  of 7%. The one-sided confidence interval at 97.5% of  
135 the difference in percentages of successful intubation will also be calculated using Wald's method.  
136 This method allows control of Type I error in a non-inferiority setting. The analysis will be performed  
137 per protocol, as recommended for non-inferiority trials, and supplemented with an intention-to-  
138 treat analysis.

## 139 Analyses of secondary outcomes

### 140 Comparisons of the Cormack and Lehane Classification in Treatment Arms

141 The classification of Cormack and Lehane evaluates the quality of the direct laryngoscopy and is  
142 coded in 4 modalities: grade 1 to 4. It is an ordinal variable with 4 modalities. The comparison of this  
143 classification between the two treatment arms will be performed using a Mann-Whitney test,  
144 adapted for ordinal variables.

### 145 Comparison of Intubation Difficult Score (IDS) in both treatment arms

146 The Intubation Difficult score (IDS) measures the overall difficulty of the intubation process. This  
147 score is a discrete quantitative variable. The comparison of this score in the two treatment arms will

148 be performed using a Student's t-test after checking the normality of the distributions and the  
149 equality of the variances.

#### 150 **Comparison of Copenhagen scores in the two treatment arms**

151 The Copenhagen score characterizes the conditions of intubation and is coded in 3 modalities. This is  
152 an ordinal variable with 3 modalities. The comparison of the Copenhagen score between the two  
153 treatment arms will be performed using a Mann-Whitney test, adapted for ordinal variables.

#### 154 **Comparisons of Intubation Devices use rates in the treatment arms**

155 Difficult intubation devices include:

- 156 - The use of Stylet
- 157 - The use of Gum Elastic bougie
- 158 - The use of Intubating laryngeal mask airway
- 159 - Cricothyrotomy

160 These are dummy variables with 2 modalities. The comparison of proportions for each device will be  
161 performed using a Chi2 test or Fisher's exact test depending on the application conditions.

#### 162 **Comparisons of proportions of immediate complications in treatment arms**

163 Immediate complications include the occurrence:

- 164 - Low blood pressure
- 165 - Severe Cardiac arrhythmia
- 166 - Cardiac arrest
- 167 - Pulmonary aspiration
- 168 - Episodes of arterial hypoxemia
- 169 - Allergic reaction.

170 These are dummy variables with 2 modalities. The comparison of proportions for each complication  
171 will be performed using a Chi2 test or an exact Fisher test according to the conditions of application.

#### 172 **Adverse events**

173 The proportions of adverse events (serious and non-severe), their intensity, study imputation, and  
174 outcome will be described in a summary table, and compared between the two treatment arms,  
175 using a Chi2 or Fisher's exact test depending on the conditions of application.

#### 176 **Concomitant treatments**

177 The frequency and proportion of treatments received in each treatment arm will be described in a  
178 descriptive table. The comparison of each proportion between the two treatment arms will be  
179 performed using a Chi2 test or an exact Fisher test according to the conditions of application.

180 In the Rocuronium group, the frequency and proportion of patients receiving Sugammadex will be  
181 estimated as well as the 95% confidence interval of this proportion.

182

183 **Subgroup analyses**

184 No subgroup analysis will be performed.

185 **Sensitivity analysis**

186 A sensitivity analysis of the primary outcome will be made by intent to treat using the method  
187 described in the primary endpoint analysis.

188 **Tables templates**

189 The table templates are shown below.

190

191 **Table 1: Characteristics of patients at baseline in the CURASMUR study**

	<b>Rocuronium (N=)</b>	<b>Succinylcholine (N=)</b>	<b>Std diff.</b>
Age, mean(SD)			
Sex, n(%)			
...			
...			

192

193

194 **Table 2: Characteristics of patients at baseline in the CURASMUR study by center**

	<b>Centre 1 (N=)</b>	<b>...</b>	<b>Centre k (N =)</b>
Age, mean(SD)			
Sex, n(%)			
...			
....			

195

196

197



Table 3: Comparison of the characteristics and complication of intubation according to the treatment arm

	Rocuronium (N=)	Succinylcholine (N=)	p-value
Successful intubation, n(%)			
Cormack and Lehane, median (IQR)			
IDS, mean (SD)			
Copenhaguen Score, median (IQR)			
Use of Stylet, n(%)			
Use of Gum Elastic bougie, n(%)			
Use of Intubating laryngeal mask airway			
Cricothyrotomy, n(%)			
Low blood pressure, n(%)			
Cardiac arrest, n(%)			
Pulmonary inhalation, n(%)			
Episodes of arterial hypoxemia, n(%)			
Allergic reaction, n(%)			

Table 4: Comparison of adverse events (AEs) according to the treatment arm

	Rocuronium (N=)	Succinylcholine (N=)	p-value
Adverse events, n(%)			
Severe Adverse Events, n(%)			
Intensity of Adverse Events			
Slight			
Moderate			
Imputable to the study			
Possible			
Doubtful			
Excluded			
Not assessable			
Evolution			
Healing without sequelae			
Healing with sequelae			
Not healed yet			
Aggravation			
Death			
Unknown			

201

202 **Table 5: Detail of adverse events according to the treatment arm**

	<b>Rocuronium (N=)</b>	<b>Succinylcholine (N=)</b>
Shock		
Hypotension		
Hypoxemia		
...		

203

204

205 **Table 6: Comparison of concomitant treatments according to the treatment arm**

	<b>Rocuronium (N=)</b>	<b>Succinylcholine (N=)</b>	<b>p-value</b>
Dobutamin, n(%)			
Ephedrin, n(%)			
Morphin, n(%)			
...			

206